A 65-year-old woman presents with frequent urination, nocturia and involuntary leakage for 6 months. Discuss causes, evaluation and management.

The symptom triad — frequency (>8 voids/24 h), nocturia (≥2 voids at night) and involuntary leakage for 6 months — is persistent incontinence with an irritative (storage) symptom profile, i.e. most likely urgency incontinence / overactive bladder, commonly mixed with stress incontinence at this age.

Age 65 with 6 months' duration excludes a purely acute/transient picture, but reversible contributors must still be sought — they are present in a large proportion of such patients.

Urgency incontinence / detrusor overactivity — idiopathic, or secondary to stone, tumour, diverticulum, outflow obstruction, or CNS disease (stroke, dementia, parkinsonism, cord lesion).

Stress incontinence — pelvic floor weakness with urethral hypermobility after childbirth, prior pelvic surgery, obesity, chronic cough and oestrogen deficiency; or intrinsic sphincter deficiency after previous vaginal repair or bladder-neck suspension.

Mixed incontinence — the commonest single answer in an older woman.

Atrophic vaginitis / urethritis — postmenopausal oestrogen deficiency causing dysuria, frequency and urgency, and predisposing to UTI.

Urinary tract infection — must be excluded; also recurrent UTI as a marker of underlying pathology.

Overflow from incomplete emptying — large cystocele or pelvic prolapse distorting the urethra, diabetic neuropathic bladder, or drug-induced retention.

Polyuria states — uncontrolled diabetes mellitus (very likely in an Indian 65-year-old), hypercalcaemia, excess fluid/caffeine, diuretics.

Nocturnal polyuria — loss of the night-time vasopressin rhythm, raised ANP, heart failure, venous insufficiency with leg oedema redistributing at night, obstructive sleep apnoea.

Malignancy — new irritative symptoms with haematuria or smoking history raise the question of bladder cancer; pelvic mass must be excluded.

Functional contributors — arthritis, poor vision, distant or Indian-style squat toilet, night-time falls risk, and drugs (sedatives, diuretics timed at night).

History: characterise leakage (with cough/laugh vs preceded by urgency vs continuous), volume, pad use, most bothersome symptom, impact on quality of life; fluid, caffeine and alcohol intake; obstetric and surgical history; diabetes, heart failure, neurological symptoms; bowel habit; full drug review; and a 3-day bladder diary.

Examination: BMI, oedema and cardiac status; abdominal palpation for a distended bladder or mass; pelvic examination for atrophic vaginitis, cystocele/prolapse grade and perineal sensation; cough stress test; rectal examination for impaction and sphincter tone; mobility, gait and cognition; focal neurology and sacral reflexes.

Bedside/basic investigations: urinalysis and, if indicated, urine culture; post-void residual by ultrasound; capillary and fasting blood glucose (mg/dL), HbA1c; serum calcium (mg/dL), creatinine (mg/dL); haemoglobin (g/dL).

Interpretation: PVR >200 mL → suspect obstruction or impaired contractility, arrange renal function and ultrasound ± urodynamics. Persistent haematuria without infection → urine cytology and cystoscopy.

Refer for gynaecological or urological/urodynamic evaluation if there is marked prolapse, ≥2 symptomatic UTIs in a year, recent pelvic surgery or irradiation, suspicion of malignancy, significant retention, or failure of an adequate therapeutic trial.

Correct reversible factors: treat UTI, relieve constipation, control diabetes, review diuretic timing, stop or substitute offending drugs, treat heart failure and leg oedema (evening leg elevation, compression stockings).

Lifestyle and conservative measures (first and always): weight reduction; fluid target of 1.5–2 L/day of non-caffeinated fluid with restriction in the evening; avoid caffeine, carbonated drinks and nicotine; treat chronic cough and constipation; safe night-time route to the toilet with a light and a bedside commode to prevent falls.

Pelvic floor muscle training, supervised, with biofeedback if available — the most effective behavioural intervention, benefiting both stress and urge components; add bladder training with progressive lengthening of the voiding interval and urge-suppression techniques.

Topical vaginal oestrogen if atrophic vaginitis is present — cream 0.5–1.0 g/day for 2 weeks then twice weekly, or an oestradiol ring 3-monthly. Never oral oestrogen.

Drug therapy if behavioural measures are insufficient: a β3-agonist (mirabegron or vibegron) is preferred in older adults; antimuscarinics (solifenacin, darifenacin, fesoterodine, trospium) are alternatives with counselling about dry mouth, constipation, glaucoma and cognitive effects. Check baseline renal function before a β3-agonist and blood pressure on treatment. Allow 4–6 weeks before judging response.

Refractory nocturia — reassess for nocturnal polyuria and sleep apnoea first; desmopressin only in carefully selected patients with close monitoring of serum sodium (mEq/L).

Refractory OAB — intradetrusor botulinum toxin A (repeat not more often than 6-monthly; counsel about retention and need for self-catheterisation) or sacral neuromodulation / posterior tibial nerve stimulation.

Predominant stress incontinence not responding to conservative care — pessary for prolapse, urethral bulking agents, or surgery (colposuspension, autologous rectus fascial sling, mid-urethral sling) after multidisciplinary discussion; counsel about long-term mesh-related uncertainty.

Review at 4–6 weeks with a repeat bladder diary, assess symptom improvement and satisfaction, and escalate or de-escalate accordingly. Address the psychosocial impact — shame, social withdrawal and depression are common and often unspoken.

AUA/SUFU 2024 allows this patient to move directly to a β3-agonist or even to botulinum toxin if bother is high — behavioural therapy no longer has to fail first, though it should always be offered.

β3-agonists over antimuscarinics is now the preferred pharmacological default in women over 65, driven by the anticholinergic–dementia signal and Beers 2023.

AUA/SUFU/AUGS Genitourinary Syndrome of Menopause Guideline 2025 endorses low-dose vaginal oestrogen for urogenital atrophy, recurrent UTI prevention and irritative symptoms, with a favourable safety profile.

Surgical caution persists: following regulatory action in several countries on synthetic mesh, autologous fascial slings and colposuspension have regained ground, and bulking agents are offered when other surgery is unsuitable.

Indian relevance: LASI data link UI in older Indian women with insomnia, sarcopenia and household biomass smoke; obstetric history of high parity and home delivery, plus squat-toilet dependence, are practical local determinants to elicit and address.

Frequency + nocturia + leakage in an older woman = OAB/urgency incontinence, usually mixed with stress.

Always exclude UTI, uncontrolled diabetes, constipation and drugs before labelling it idiopathic.

3-day bladder diary separates nocturnal polyuria from a storage problem.

Cough stress test with an empty bladder in the supine position suggests intrinsic sphincter deficiency.

PVR >200 mL changes the whole management plan — always measure it.

Pelvic floor muscle training helps both the stress and the urge component.

Vaginal, not oral, oestrogen for atrophic vaginitis.

β3-agonist first in the elderly; review at 4–6 weeks.

New irritative symptoms + haematuria + smoking = exclude bladder cancer.